



## **Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism**

June 12, 2023

**This family of drug candidates of SERCA2a Activators have similar mechanisms of action to istaroxime and may lead to novel therapies for heart failure**

WARRINGTON, Pa., June 12, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today reported that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its patent application covering the Company's dual mechanism SERCA2a Activators. The U.S. Patent Application is No. 17/263,209. A notice of allowance is issued by the USPTO to indicate that the application has passed examination.

The Company previously reported that the European Patent Office granted Patent No. 3599243, providing patent coverage for the dual mechanism SERCA2a Activator class of drug candidates. Windtree has preclinical drug candidates with dual mechanisms of action (inhibition of the Na<sup>+</sup>/K<sup>+</sup> pump and activation of SERCA2a) as well as pure SERCA2a activators (devoid of action on the Na<sup>+</sup>/K<sup>+</sup> pump). The U.S. patent scheduled to issue from this application is titled: "17BETA-HETEROCYCLYL-DIGITALIS LIKE COMPOUNDS FOR THE TREATMENT OF HEART FAILURE."

Like istaroxime, the intravenous late-stage development candidate for treatment of acute decompensated heart failure and cardiogenic shock, the dual mechanism compounds activate SERCA2a and inhibit the Na<sup>+</sup>/K<sup>+</sup> pump. However, these product candidates are intended to be both oral and IV therapies and may represent a hospital inpatient therapy for acute decompensated heart failure as well as outpatient, oral therapy for hospital discharge and chronic heart failure treatment.

"We are pleased to see the continued progress of our IP portfolio strategy for the dual mechanism SERCA2a Activator family of drug candidates," said Craig Fraser, CEO and President of Windtree Therapeutics. "The development strategy with these dual mechanism compounds is for potential 'fast follow-on' drug candidates that can leverage the experience with istaroxime and provide the potential added feature of oral bioavailability for use as a treatment for chronic heart failure. This composition of matter patent represents a key part in our plan for these assets and we look forward to the next step in the process from the USPTO."

### **About Dual Mechanism SERCA2a Activators**

Dual Mechanism SERCA2a Activators activate SERCA2a and inhibit the Na<sup>+</sup>/K<sup>+</sup> pump. Windtree Therapeutic's research program is evaluating these preclinical product candidates, including oral and intravenous SERCA2a Activator heart failure compounds.

### **About Istaroxime**

Istaroxime is a first-in-class dual mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na<sup>+</sup>/K<sup>+</sup> ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with acute heart failure (AHF) demonstrate that istaroxime infused intravenously significantly improves cardiac function and blood pressure without increasing heart rate or the incidence of cardiac rhythm disturbances.

### **About Windtree Therapeutics, Inc.**

Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for cardiovascular disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree's heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on facilitating the transfer of the KL4 surfactant platform, to its licensee, Lee's Pharmaceutical (HK) Ltd. Included in Windtree's portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include: risks and uncertainties associated with the economic and social consequences of the COVID-19 pandemic, including any adverse impact on the Company's clinical trials, clinical trial timelines or disruption in supply chain; the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates; the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets; the Company's ability to secure significant additional capital as and when needed; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous

regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; and the rate and degree of market acceptance of the Company's product candidates, if approved. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at [www.sec.gov](http://www.sec.gov). Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

**Contact Information:**

Monique Kosse  
LifeSci Advisors  
212.915.3820 or [monique@lifesciadvisors.com](mailto:monique@lifesciadvisors.com)

Media:  
Katie Larch / Robert Flamm, Ph.D.  
Burns McClellan, Inc.  
[klarch@burnsmc.com](mailto:klarch@burnsmc.com) / [Rflamm@burnsmc.com](mailto:Rflamm@burnsmc.com)



Source: Windtree Therapeutics